ADDRESS-2 is a partner in the Type 1 Diabetes UK Immunotherapy Research Consortium
Finding new and better treatments for type 1 diabetes
T1DUK aims to:
- Develop and conduct new trials in type 1 diabetes
- Make the UK one of the best places to run trials
- Learn as much as we can about every participant in every trial